2-乙氧基-5-硝基苯甲醛 | 741738-54-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙氧基-5-硝基苯甲醛
• 英文名称: 2-ethoxy-5-nitrobenzaldehyde
• CAS: 741738-54-5
• 化学式: C₉H₉NO₄
• mdl: MFCD00774368
• 分子量: 195.175
• InChiKey: FIRASLIMSQEZFO-UHFFFAOYSA-N

物化性质

• 熔点：
  70-72 °C
• 沸点：
  346.0±27.0 °C(Predicted)
• 密度：
  1.271±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-乙氧基-5-硝基苯甲醛 生成 2-ethoxy-5-nitrobenzoic acid
  参考文献：
  名称：

  Gattermann, Justus Liebigs Annalen der Chemie, 1912, vol. 393, p. 224

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙氧基苯甲醛 生成 2-乙氧基-5-硝基苯甲醛
  参考文献：
  名称：

  Clayton, Journal of the Chemical Society, 1910, vol. 97, p. 2106

  摘要：

  DOI：

文献信息

• Syntheses of heterocyclic compounds. Part XXIV. Cyclisation studies with ortho-substituted arylcarbene and arylnitrene precursors
  作者：G. V. Garner、D. B. Mobbs、H. Suschitzky、J. S. Millership

  DOI：10.1039/j39710003693

  日期：——

  indolines. The scope and mechanism of this cyclisation have been explored. Moreover, benzaldehyde tosylhydrazones with o-alkoxy-, o-thioalkyl-, and o-phosphonate substituents as well as the corresponding diazoalkanes were pyrolysed and photolysed. The products from these carbene precursors were compared with those obtained from the analogous nitrene precursors [i.e. ArN3 or ArNO2+(RO)3P].

  邻二烷基氨基取代的苯甲醛的甲苯磺酰的热分解和光分解产生二氢吲哚。已经探索了这种环化的范围和机理。此外，苯甲醛甲苯磺酰腙与ø -烷氧基- ，ø -thioalkyl-，和ø -膦取代基以及相应的重氮烷进行热解和光解。从这些前体的碳烯的产物与来自类似的氮宾的前体[获得的那些进行比较即ARN 3或ARNO 2 +（RO）3 P]。
• Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity
  作者：Wen-Chao Chu、Peng-Yan Bai、Zhao-Qing Yang、De-Yun Cui、Yong-Gang Hua、Yi Yang、Qian-Qian Yang、En Zhang、Shangshang Qin

  DOI：10.1016/j.ejmech.2017.12.009

  日期：2018.1

  an urgent need to identify new antibiotics with novel mechanisms that combat antibiotic resistant bacteria. Herein, a series of chalcone derivatives that mimic the essential properties of cationic antimicrobial peptides were designed and synthesized. Antibacterial activities against drug-sensitive bacteria, including Staphylococcus aureus, Enterococcus faecalis, Escherichia coli and Salmonella enterica

  迫切需要鉴定具有对抗抗生素抗性细菌的新机制的新抗生素。本文中，设计并合成了一系列模仿阳离子抗微生物肽基本特性的查尔酮衍生物。对包括金黄色葡萄球菌，粪肠球菌，大肠杆菌和沙门氏菌在内的药物敏感细菌的抗菌活性，以及耐甲氧西林金黄色葡萄球菌（MRSA），KPC-2产生和NDM-1-的临床多重耐药菌株评价产生耐碳青霉烯的肠杆菌科细菌。代表性化合物5a（MIC：1μg/ mL金黄色葡萄球菌，针对MRSA的0.5μg/ mL）和5g（MIC：针对金黄色葡萄球菌的0.5μg/ mL，针对MRSA的0.25μg/ mL）对革兰氏阳性菌和革兰氏阴性菌均具有良好的杀菌活性，包括该药物耐药菌种MRSA，KPC和NDM。已证明这些具有膜活性的抗菌化合物可有效减少细菌生物膜中的活细胞数，并且不会诱导细菌产生抗药性。另外，在合适的浓度下，这些代表性分子对哺乳动物细胞的毒性可忽略不计。综合结果表明，该系列阳离子查耳酮衍生物具有抗细菌感染的潜在治疗作用。
• Breast cancer resistance protein (bcrp) inhibitor
  申请人：Yamazaki Ryuta

  公开号：US20060128636A1

  公开（公告）日：2006-06-15

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH 3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR 1 (R 1 is hydrogen or C1-C4 alkyl), —O(CH 2 ) n COOR 2 (n=1−7: R 2 is hydrogen or C1-C4 alkyl), —OOCCH 2 CH 2 COOR 3 (R 3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH) 2 ) or a salt thereof, a sulfate group (i.e., —OSO 3 H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  本发明提供了一种抑制BCRP的药物。一种含有以下式（1）所表示的二苯乙烯腈衍生物作为活性成分的乳腺癌耐药蛋白抑制剂：[其中，8个R分别表示氢原子、羟基、硝基、氨基、乙酰氨基（—NHCOCH3基）、氰基（—CN基）、甲酰基（—CHO基）、—COOR1（R1为氢或C1-C4烷基）、—O（CH2）nCOOR2（n = 1-7：R2为氢或C1-C4烷基）、—OOCCH2CH2COOR3（R3为氢、C1-C4烷基、（Z）-2-（3,4-二甲氧基苯基）-3-（4-羟基苯基）-丙烯腈或葡萄糖基）、C1-C8烷氧基、C1-C4烷基、卤原子、C1-C4烷氧基C1-C4烷氧基C1-C4烷氧基、C2-C8酰氧基、C2-C8卤代酰氧基、亚甲二氧基基团、三氟甲基基团、磷酸酯基团（即—OP（O）（OH）2）或其盐、硫酸酯基团（即—OSO3H）或其盐、葡萄糖基或其盐、葡萄糖基的磷酸酯或酯的盐、葡萄糖基的硫酸酯或酯的盐，或者是它的酯或盐。
• Breast cancer resistance protein (BCRP) inhibitor
  申请人：Kabushiki Kaisha Yakult Honsha

  公开号：US07371773B2

  公开（公告）日：2008-05-13

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1−7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., —OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  该发明提供了一种抑制BCRP的药物。一种含有以下式（1）所表示的二苯丙烯腈衍生物作为活性成分的乳腺癌耐药蛋白抑制剂：[其中，8个R，它们相同或不同，分别表示氢原子，羟基，硝基，氨基，乙酰氨基（—NHCOCH3基），氰基（—CN基），甲酰基（—CHO基），—COOR1（R1为氢或C1-C4烷基），—O（CH2）nCOOR2（n = 1-7：R2为氢或C1-C4烷基），—OOCCH2CH2COOR3（R3为氢，C1-C4烷基，（Z）-2-（3,4-二甲氧基苯基）-3-（4-羟基苯基）-丙烯腈或甘露糖基），C1-C8烷氧基，C1-C4烷基，卤原子，C1-C4烷氧基C1-C4烷氧基C1-C4烷氧基，C2-C8酰氧基，C2-C8卤代酰氧基，亚甲二氧基基团，三氟甲基基团，磷酸盐基（即—OP（O）（OH）2）或其盐，硫酸盐基（即—OSO3H）或其盐，甘露糖基或其盐，甘露糖基的磷酸酯或其盐，甘露糖基的硫酸酯或其盐，或哌啶基哌啶羧酰氧基]，其酯或其盐。
• BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR
  申请人：KABUSHIKI KAISHA YAKULT HONSHA

  公开号：EP1591117A1

  公开（公告）日：2005-11-02

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (-NHCOCH3 group), a cyano group (-CN group), a formyl group (-CHO group), -COOR1 (R1 is hydrogen or C1-C4 alkyl) , -O(CH2)nCOOR2 (n=1-7: R2 is hydrogen or C1-C4 alkyl) , -OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., -OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., -OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  本发明提供了一种抑制 BCRP 的药物。 一种乳腺癌抗性蛋白抑制剂，其活性成分含有下式（1）所代表的二苯基丙烯腈衍生物： [其中，8 个彼此相同或不同的 R 的每一个代表氢原子、羟基、硝基、氨基、乙酰氨基（-NHCOCH3 基）、氰基（-CN 基）、甲酰基（-CHO 基）、-COOR1（R1 是氢或 C1-C4 烷基）、-O(CH2)nCOOR2（n=1-7：R2是氢或C1-C4烷基），-OOCCH2CH2COOR3（R3是氢、C1-C4烷基、(Z)-2-(3,4-二甲氧基苯基)-3-(4-羟基苯基)-丙烯腈或吡喃糖基），C1-C8烷氧基，C1-C4烷基、C1-C4 烷氧基、C2-C8 酰氧基、C2-C8 卤代酰氧基、亚甲基二氧基、三氟甲基、磷酸基团（即e.,-OP(O)(OH)2）或其盐、硫酸基（即-OSO3H）或其盐、吡喃糖基或其盐、吡喃糖基的磷酸酯或其酯盐、吡喃糖基的硫酸酯或其酯盐、哌啶基哌啶羰基氧基]、其酯或其盐。